JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio sold its Ireland vaccine facility to Merck (MRK) for about $500M sent the stock lower, the firm thinks the company sold the facility not mainly due to “Biosecure Act” pressure, but due to the low investment return of the facility, the analyst tells investors. The firm expects WuXi Bio’s order growth might improve given that the “Biosecure Act” bill failed to pass in the U.S. in 2024, the analyst added.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Paychex to acquire Paycor HCM, Getty and Shutterstock to merge: Morning Buzz
- Wuxi Biologics to sell Irish vaccine facility to Merck for $500M, Reuters says
- Opko Health subsidiary announces EBV vaccine enters Phase I study
- Merck put volume heavy and directionally bearish
- Drug Prices Are Increasing Again in 2025, But It’s Not as Bad as It Sounds
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
